The ALLG Biobank is located at the Hunter Cancer Biobank (HCB) Newcastle, New South Wales, Australia.
The HCB was established in 2012 as a joint initiative of Hunter Cancer Research Alliance (HCRA), Pathology North (Hunter New England) and Hunter New England Local Health District (HNE LHD). HCB values the delivery of high quality services and operates in accordance with all national and international guidelines.
A biobank is a central repository of human tissue samples from blood, bone marrow or other tissue. The biobank receives and stores specimens from patients with haematological malignancies participating in ALLG investigator initiated clinical trials and the ALLG National Blood Cancer Registry (NBCR).
The aim of the biobank is to facilitate the conduct of research thereby augmenting the benefits of our clinical research into haematological malignancies. The function of the biobank will be to provide samples from patients with these diseases for use in ethically approved research projects thereby facilitating a wide range of research activities. The ultimate goal of facilitating such research is to improve our understanding of the processes leading to the development of haematological malignancies, factors which govern the variable response to current treatments and ultimately the development of more effective therapies for patients suffering from haematological malignancies.
Facilitating research from fully characterized clinical samples will assist to harmonise relationships between Australia’s internationally renowned researchers and ALLG’s internationally recognized clinical research in the field of Haematology, Oncology and Bone Marrow Transplant. Together we can anticipate better understanding of the events leading to the development of haematological malignancies and of factors contributing to patient’s outcome, which will ultimately lead to better therapies and outcomes for patients.
The ALLG has developed a sound and reliable Ethical Defensible Plan (EDP) in accordance with the NHMRC Ethical Conduct of Human Research section 3.5.1 “Where research may discover or generate information of potential importance to the future health of participants or their blood relatives, researchers must prepare and follow an ethically defensible plan to disclose or withhold that information”. This will describe management of any proposed disclosure or non-disclosure from biobank related research (investigator initiated clinical trials).
Return of medically significant research findings (SOP ID NUMBER: EDP VERSION 1.0)
Document Size: 174Kb Uploaded: 27 June 2018 Modified: 27 June 2018
The Biobank Sample Pathway
Represents ALLG Sample Pathway – AML Patients / ALL Patients
The Biobank Coordinator
ALLG has appointed a biobank coordinator to manage the operations and logistics of biobanking. The biobank coordinator is the point of contact for all ALLG members, trial centre and committees, and will facilitate workflow between the ALLG and HCB. The coordinator will assist with researcher requests for samples & data, and provide scientific and technical guidance (shipping, sample processing, and protocol development).
For enquiries regarding the Biobank, please contact:
NBCR & Biobank Coordinator
+61 3 8373 9725